Pharmacogenomic Testing for Pediatric Cancer Patients
This study is looking at how genetic testing can help personalize treatment for children and young adults with cancer. It involves a special test called pharmacogenomic (PGx) testing, which analyzes your genes to see how your body might react to certain medications. The goal is to understand how often gene-drug interactions happen in pediatric cancer patients and how these genetic insights can help doctors choose the best anti-cancer therapies and supportive care medications for you. You can join if you are 26 years old or younger, have a new cancer diagnosis, or are preparing for a bone marrow transplant. The study aims to enroll 130 participants. The current recruitment status is unclear.
- Study design
- This is an interventional, single-arm study, meaning all participants will receive the pharmacogenomic testing. It plans to enroll 130 participants.
- What's involved
- You would provide a buccal (cheek) swab for genetic testing at the time of enrollment. Your test results will be added to your medical record and reviewed by your doctors.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your gene-drug interactions will be measured at 3, 6, 9, and 12 months after you enroll in the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Erin Trovillion, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Gene-drug interaction3, 6, 9, 12 months after enrollment
A gene-drug interaction occurs when an individual carrying a variant form of a gene is administered a drug that serves as a substrate for the enzyme or transporter encoded by that gene. Clinically relevant gene-drug interactions are defined in the CPIC (Clinical Pharmacogenetics Implementation Consortium) guidelines or the FDA Table of Pharmacogenomic Associations. Gene-drug interaction is a binary variable (interaction present or interaction absent). Each clinically relevant gene-drug interaction from the pharmacogenomic testing will be reported.
- GenotypeBaseline
Genes involved in toxicity and efficacy of pediatric anticancer therapy and supportive care medications, as listed in CPIC or FDA Table of Pharmacogenomic Association guidelines, are tested for genetic polymorphisms using the OneOme RightMed Comprehensive Test. Each gene's genotype is classified as a binary variable (actionable or not actionable).